<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159740">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01884194</url>
  </required_header>
  <id_info>
    <org_study_id>RTB_0305_outcome</org_study_id>
    <nct_id>NCT01884194</nct_id>
  </id_info>
  <brief_title>Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging</brief_title>
  <official_title>Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MRI is useful for diagnosing pinealoblastoma in retinoblastoma patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Malignancy criteria of pineal gland</measure>
    <time_frame>clinical follow-up 1-year after baseline imaging</time_frame>
    <safety_issue>No</safety_issue>
    <description>size of pineal gland solid or cystic component (all at baseline)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Retinoblastoma</condition>
  <condition>Pineoblastoma</condition>
  <arm_group>
    <arm_group_label>Retinoblastoma patients</arm_group_label>
    <description>patients with diagnosed retinoblastoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-retinoblastoma patients</arm_group_label>
    <description>aged matched control cohort without the diagnosis of ocular or brain tumor</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        pediatric patients with retinoblastoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of retinoblastoma

          -  brain MRI available

        Exclusion Criteria:

          -  insufficient quality of brain MRI
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick Asbach, MD</last_name>
    <phone>+4930450527723</phone>
    <email>patrick.asbach@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite Hospital Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Asbach, MD</last_name>
      <phone>+4930450527723</phone>
      <email>patrick.asbach@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 11, 2013</lastchanged_date>
  <firstreceived_date>May 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Thi Thai Hien Pham</investigator_full_name>
    <investigator_title>doctoral candidate</investigator_title>
  </responsible_party>
  <keyword>retinoblastoma</keyword>
  <keyword>pineoblastoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Pinealoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
